The Johnson & Johnson Hip Implant Case and Its Ripple Effect on Medical Device Regulation in India
The Johnson & Johnson (DePuy) ASR hip implant controversy stands as a landmark medical device case that exposed the fragile regulatory architecture governing implantable medical devices in India. Unlike conventional pharmaceutical products, medical devices—especially implants—pose long-term, irreversible risks when quality or design failures occur. This case brought that reality into sharp focus.
Thousands of patients in India received the metal-on-metal ASR hip implants, which were later found to have high failure rates due to metal wear. Over time, these implants released cobalt and chromium ions into patients’ bodies, leading to severe pain, tissue damage, inflammation, and systemic toxicity. The most disturbing aspect was not merely the device failure, but the absence of a robust system to monitor, recall, or compensate affected patients promptly.
Legal action and public interest litigation revealed that, at the time of approval and widespread use, India lacked a dedicated medical device regulatory framework. Implants were regulated under the Drugs and Cosmetics Act, 1940, which was never designed to address the complexity of device design, post-market surveillance, or device-specific clinical evaluation. There were no clear rules for tracking implant performance, reporting device-related adverse events, or defining manufacturer liability.
The judiciary’s intervention became a turning point. The Supreme Court of India directed the government to investigate the matter, assess patient harm, and establish a compensation mechanism. An expert committee was formed, which not only examined the J&J case but also evaluated systemic failures in medical device regulation. The findings were clear: India needed a separate, risk-based regulatory framework for medical devices, aligned with global best practices.
As a direct consequence, India accelerated reforms that eventually led to the Medical Device Rules (MDR), 2017. These rules introduced device classification based on risk, mandatory clinical investigations for high-risk implants, post-market surveillance obligations, and clearer pathways for recalls and corrective actions. The case also emphasized the importance of materiovigilance, resulting in the establishment of the Materiovigilance Programme of India (MvPI).
For the pharmaceutical and medical device industry, this case marked a cultural shift. Device manufacturers were compelled to adopt lifecycle-based quality systems, clinical evidence generation, and long-term safety monitoring. Regulators transitioned from a product-centric to a patient-centric oversight model. Most importantly, patients’ rights and safety became central to regulatory decision-making.
This case did not merely resolve a single product failure; it reshaped the entire medical device ecosystem in India, pushing it toward transparency, accountability, and global regulatory convergence.
MBH/AB